EDAP to Ring the NASDAQ Stock Market Closing Bell On Dec. 17

Celebrating Launch of U.S. Study and 10 Years as NASDAQ Company

CEO, CFO and Medical Director Available for Media Interviews

LYON, France, Dec. 14, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announces CEO Marc Oczachowski will ring the NASDAQ closing Bell on Monday, December 17, 2007 to celebrate the launch of its U.S. Clinical Study programs and EDAP's 10 years as a NASDAQ listed company. EDAP will also host investor meetings and media interviews throughout the day at the NASDAQ headquarters located at Times Square in New York.

"Indeed, this Closing Bell Ceremony is a celebration of our accomplishments to date, but more importantly we celebrate our potential as we look toward the future," commented Oczachowski. "We are launching a clinical program in the United States to evaluate and seek FDA approval for Ablatherm HIFU, which is an innovative non invasive treatment for localized prostate cancer. Prostate cancer is the most commonly diagnosed cancer in American men, which affects over 200,000 American men and their families every year."

Oczachowski continued, "EDAP has recently raised $20 million through a convertible pipe to completely finance our FDA approved IDE clinical investigation of Ablatherm HIFU. There is not a better opportunity and more appropriate place than today at NASDAQ to celebrate and declare open the next chapter of the EDAP story in America. EDAP, as a world leader in Therapeutic Ultrasound, is now officially and fully focused on the American market. Many of the World's top cancer research centers will be participating in the IDE investigation, and I want to take this opportunity to thank them again for their confidence in our technology, their enthusiasm, and their support."

Company Background:

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. The company is currently in U.S. FDA Phase II/III Clinical Trials at major U.S. centers including Duke University, Vanderbilt University, Florida Foundation of Healthcare, and others. Participating sites can be viewed online at www.clinicaltrials.gov by searching for "Ablatherm."

Ablatherm-HIFU is fully approved in the EU and other countries worldwide. More than 14,500 treatments have been completed at more than 165 centers globally. Clinical documentation compiled over more than 10 years provides peer reviewed data attesting to efficacy, safety and repeatability of the treatment outcomes among centers.

Ablatherm-HIFU is a treatment for patients with newly diagnosed localized prostate cancer or who have failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

To sign up for alerts please visit: http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT: EDAP TMS S.A.
Blandine Confort
+33 4 78 26 40 46

Magnolia Investor Relations

Matt Kreps
469-362-5960